Top Markets
Coin of the day
AbbVie Inc. AbbVie Inc.

AbbVie Inc.

ABBV
शेयरों में रैंक #30
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the... AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
शेयर मूल्य
$208.57
मार्केट कैप
$368.78B
बदलाव (1 दिन)
0.68%
बदलाव (1 वर्ष)
3.61%
देश
US
व्यापार AbbVie Inc. (ABBV)

श्रेणी

AbbVie Inc. (ABBV) के लिए डिविडेंड यील्ड इतिहास
AbbVie Inc. (स्टॉक सिंबल: ABBV) की डिविडेंड यील्ड (TTM) 2024-12-31 को: 3.51%
पिछले 5 वर्षों की औसत डिविडेंड यील्ड: 3.52%
AbbVie Inc. (ABBV) के लिए 2009 से 2026 तक की डिविडेंड यील्ड का इतिहास
प्रत्येक वर्ष के अंत में डिविडेंड यील्ड (TTM)
वर्ष डिविडेंड यील्ड परिवर्तन
2026 (TTM) 3.03% 5.57%
2025 2.87% -18.23%
2024 3.51% -8.83%
2023 3.85% 9.69%
2022 3.51% -9.07%
2021 3.86% -10.65%
2020 4.32% -10.93%
2019 4.85% 23.41%
2018 3.93% 47.74%
2017 2.66% -27.32%
2016 3.66% 7.02%
2015 3.42% 34.12%
2014 2.55% -16.12%
2013 3.04% 0.00%
2012 0.00% 0.00%
2011 0.00% 0.00%
2010 0.00% 0.00%
2009 0.00% 0.00%
समान कंपनियों या प्रतिस्पर्धियों के लिए डिविडेंड यील्ड (TTM)
कंपनी डिविडेंड यील्ड देश
0.63%
US
1.64%
GB
2.15%
US
3.05%
CH
2.84%
US